Shareholders in the old entity kept their shares and received one new share of Abraxis BioScience for every four they owned of the old company. This deal appeared to work out for investors, as APP Pharmaceuticals was bought out by Fresenius, a large German healthcare company involved in dialysis services, for $4.6 billion in the fall of 2008. Abraxis BioScience is down only 11% over the last year as of the close on March 11, compared to the S&P 500's drop of 44%.
http://community.investopedia.com/news/IA/2009/Spinoffs-Revisited-DISH-ABII-SATS0313.aspx?partner=YahooSA
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM